Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

110 results
Display

Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma

An J, Yoo Y, Kim HG, Woo J, Lee KE, Kwon H, Lim W, Sung SH, Paik NS, Moon BI

Squamous cell carcinoma of the breast and its subtype, basal-human epidermal growth factor receptor 2 (HER2) phenotype, are very rare. Herein, we report a patient who developed recurrence of squamous...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of cobas EGFR Mutation Test v2 and PANAMutyper-R-EGFR for Detection and Semi-Quantification of Epidermal Growth Factor Receptor Mutations in Plasma and Pleural Effusion Supernatant

Han AL, Kim HR, Choi KH, Hwang KE, Zhu M, Huang Y, Wu M, Lee YJ, Park MC, Cho JH, Park DS

BACKGROUND: Plasma epidermal growth factor receptor (EGFR) mutation tests are less invasive than tissue EGFR mutation tests. We determined which of two kits is more efficient: cobas EGFR Mutation test...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy

Jang Y, Cho EY, Cho SY

Mucinous carcinoma (MC) is a rare subtype of breast cancer, which is composed of tumor cells floating in the abundant extracellular mucin. This form of cancer is usually estrogen receptor/progesterone...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Discordance of Epidermal Growth Factor Receptor Mutation between Brain Metastasis and Primary Non-Small Cell Lung Cancer

Kim KM, Lee SH, Kim SM, Kim NY, Gwak HS, Shin SH, Kwon JW, Yoo H

BACKGROUND: The aim of this study was to compare epidermal growth factor receptor (EGFR) mutations between non-small cell lung cancer (NSCLC) and corresponding brain metastases (BMs) in Korea society. METHODS: From...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

Kim JM, Choung S, Joung KH, Lee JH, Kim HJ, Ku BJ

We analyzed circulating soluble epidermal growth factor receptor (sEGFR) levels in humans. Serum sEGFR levels were higher in subjects with newly diagnosed type 2 diabetes mellitus compared with controls. Serum...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results

Paik HJ, Choi HJ, Ryu JM, Park S, Kim I, Lee SK, Yu J, Kim SW, Nam SJ, Lee JE

PURPOSE: Accurate human epidermal growth factor receptor 2 (HER2) status is important in predicting prognosis and providing treatment for HER2-positive breast cancer patients. However, performing in situ hybridization (ISH) can...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Implications According to Diagnostic Methods of Human Epidermal Growth Factor Receptor 2 Positivity in Breast Cancer: A Retrospective Study

Kim BK, Jeong J, Han W, Yoon TI, Seong MK, Jung JH, Jung SH, Lee J, Sun WY, Korean Breast Cancer Society

PURPOSE: According to American Society of Clinical Oncology/College of American Pathologists guidelines, breast cancer is human epidermal growth factor receptor 2 (HER2) positive if there is HER2 protein overexpression at...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis

Seo Y, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY

PURPOSE: PIK3CA mutation is considered to be a possible cause for resistance to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the association...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer

Yun S, Kwak Y, Nam SK, Seo AN, Oh HK, Kim DW, Kang SB, Lee HS

PURPOSE: Molecular treatments targeting epidermal growth factor receptors (EGFRs) are important strategies for advanced colorectal cancer (CRC). However, clinicopathologic implications of EGFRs and EGFR ligand signaling have not been fully...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, Chen JJ, Chen HW, Yu SL, Yang TY, Chang GC

PURPOSE: The main objective of this study was to investigate the relationship among the clinical characteristics and the frequency of T790M mutation in advanced epidermal growth factor receptor (EGFR)–mutant lung...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer

Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK

BACKGROUND/AIMS: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

Park HK, Seo Y, Choi YL, Ahn MJ, Han J

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Basaloid Squamous Cell Carcinoma of the Head and Neck: Subclassification into Basal, Ductal, and Mixed Subtypes Based on Comparison of Clinico-pathologic Features and Expression of p53, Cyclin D1, Epidermal Growth Factor Receptor, p16, and Human Papillomavirus

Cho KJ, Jeong SU, Kim SB, Lee SW, Choi SH, Nam SY, Kim SY

BACKGROUND: Basaloid squamous cell carcinoma (BSCC) is a rare variant of squamous cell carcinoma with distinct pathologic characteristics. The histogenesis of BSCC is not fully understood, and the cancer has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer

Kim A, Jang MH, Lee SJ, Bae YK

PURPOSE: Epidermal growth factor receptor (EGFR) is considered a potential therapeutic target for anti-EGFR therapy in triple-negative breast cancer (TNBC). However, the frequency of EGFR gene mutation in TNBC is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy

Kim MK, Lee SE, Sohn JS, Choi IS, Moon JI, Yoon DS, Chun KW, Lee HY, Sung NS, Park SM, Choi WJ

PURPOSE: This study aimed to clarify the association between human epidermal growth factor receptor 2 (HER-2) status and the clinicopathologic factors of patients who underwent curative intent gastrectomy. METHODS: From June...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

Choi YW, Choi JH

An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers

Lee SJ, Hwang CS, Kim YK, Lee HJ, Ahn SJ, Shin N, Lee JH, Shin DH, Choi KU, Park DY, Lee CH, Huh GY, Sol MY, Lee HJ, Gong G, Kim JY, Kim A

PURPOSE: The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. Interferons can affect T-cell activity through direct and indirect mechanisms. Myxovirus resistance A (MxA) is an...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer

Seo KW, Jeon T, Kim S, Kim SS, Kim K, Suh BJ, Hwang S, Choi S, Ryu S, Min JS, Lee YJ, Jee YS, Chae H, Yang DH, Lee SH

PURPOSE: The Trastuzumab for gastric cancer (GC) trial identified human epidermal growth factor receptor 2 (HER2) as a predictor of successful treatment with trastuzumab (HER2 receptor targeting agent) among patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Value of Estrogen and Progesterone Receptor Expression in Low Proliferative Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Lee Y, Park I, Cho H, Yang K, Kim J, Park K, Gwak G

PURPOSE: Approximately two-thirds of breast cancer are estrogen-dependent cancers, which express estrogen receptor (ER)/progesterone receptor (PR). We investigated the prognostic value of ER/PR expression in human epidermal growth factor receptor 2...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr